Results 231 to 240 of about 24,787 (310)

Dupilumab in patients with cold urticaria: Results from a phase 3 trial. [PDF]

J Allergy Clin Immunol Glob
Metz M, Saini SS, Yagami A, Gagnon R, Giménez-Arnau AM, Luo X, Robinson LB, Martinčová R, Radin A, Makhija M.   +9 more
europepmc   +1 more source

Dupilumab as an Innovative Therapy for Symptomatic Management of Chemotherapy-Induced Pruritus: A Case Series [PDF]

Nupur Singh, Anna Conner, Zachary Nahmias   +2 more
openalex   +1 more source

Innate Lymphoid Cells in Tissue Homeostasis and Diseases

MedComm, Volume 7, Issue 5, May 2026.
Innate lymphoid cells (ILCs) are a heterogeneous group of immune cells with phenotypic and functional plasticity. ILCs dynamically regulate various immune cell types and play a crucial role in the pathophysiological processes of specific organs during sepsis. Targeting ILCs is a promising strategy for treating sepsis.
Zhenzhen Zhan, Heyang Sun, Chenning Li, Qianya Hong, Shuainan Zhu, Ying Yu, Hao Zhang, Kefang Guo   +7 more
wiley   +1 more source

Development of a clinical indicator-based severity scoring system for pediatric atopic dermatitis and evaluation of dupilumab treatment outcomes. [PDF]

Am J Transl Res
Ding P, Zhang D, Deng X, Shi H.
europepmc   +1 more source

Molecular characterization of atopic dermatitis:a meta-analysis [PDF]

, 2016
Ewald, David Adrian
core  

Real‐World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry

United European Gastroenterology Journal, Volume 14, Issue 4, May 2026.
ABSTRACT Background Upadacitinib (UPA) is the first oral Janus kinase (JAK) inhibitor approved for the treatment of Crohn's disease (CD). Real‐world data, particularly from large nationwide cohorts, remain limited. This study aimed to evaluate the real‐world effectiveness, safety, and treatment persistence of UPA in patients with CD.
M. Iborra, B. Botella, M. D. Martín‐Arranz, D. Ceballos, C. Martínez‐Pascual, A. Garrido, P. Varela, M. Moreta, E. Brunet‐Mas, Y. González‐Lama, E. Rodríguez‐González, M. Vicuña, J. P. Gisbert, I. Ordás, F. Argüelles‐Arias, J. Tosca‐Cuquerella, R. Vicente‐Lidón, M. Sierra‐Ausín, I. Rodríguez‐Lago, D. Martín‐Rodríguez, J. M. Paredes, B. Sicilia, I. García de la Filia, N. Jiménez, M. Barreiro‐de Acosta, E. Betoré, I. Ferrer‐Bradley, L. García‐Alles, J. M. Huguet, S. Castellet‐Farrús, M. J. García, A. Gutiérrez‐Casbas, Á. Ponferrada‐Díaz, L. Ramos, M. Calafat, I. Vera, C. Suárez‐Ferrer, E. Fernández‐Velado, S. Rodríguez‐Sánchez, A. Mínguez, A. Mancebo, J. Barrio, S. Lario, D. R. de La Cruz, Alejandro Hernández‐Camba, C. Rodríguez‐Gutiérrez, M. Chaparro, E. Ricart, L. Almenara‐Michelena, A. Balaguer, E. Domènech, P. Nos   +51 more
wiley   +1 more source

Matching-adjusted indirect comparison analysis of omalizumab versus dupilumab in patients with chronic spontaneous urticaria. [PDF]

J Allergy Clin Immunol Glob
Mosnaim G, Seetasith A, Holden M, Trzaskoma BL, Saini SS.   +4 more
europepmc   +1 more source

Dupilumab-Related Adverse Events and Intolerance in Aspirin-Exacerbated Respiratory Disease Patients. [PDF]

Int Forum Allergy Rhinol
Herpin LP, Bach R, Bruneto R, Faltas KA, Kohanski MA, Palmer JN, Adappa ND, Douglas JE, Bosso JV.   +8 more
europepmc   +1 more source

DUPILUMAB: A NEW ALLY FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS?

Lara Zaccarelli Rubira, Marcela Pereira Romão, Ethel Zimberg Chehter   +2 more
openalex   +2 more sources

Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial [PDF]

Mario Castro, Alberto Papi, Celeste Porsbjerg, Njira Lugogo, Christopher E Brightling, Francisco Javier González‐Barcala, Arnaud Bourdin, Мykola Ostrovskyy, Maria Staevska, Pai-Chien Chou, Liliana Duca, Ana Margarida Pereira, Charles Fogarty, Rufai Nadama, Mei Zhang, Amelie Rodrigues, Xavier Soler, Harry Sacks, Yamo Deniz, Paul J. Rowe, Lucía De Prado Gómez, Juby A Jacob-Nara   +21 more
openalex   +1 more source